[Skip to content]

Cancer Advice - from leading UK Cancer Specialists
Find information
In this section...
On this site...

Sunitinib therapy in kidney cancer

A recent study presented at the American Society for Clinical Oncology annual meeting, compared therapy with sunitinib (an inhibitor of the effector pathway of the VHL oncogene)with interferon (standard current therapy) for metastatic kidney cancer (clear cell carcinoma - the commonest form of the disease). In a previous study, there had been a 40% objective response rate observed for sunitinib therapy in this situation. In the reported trial, therapy with sunitinib was more likely to cause a response in the disease than interferon. This trial and others, which are expected to confirm these results (both for sunitinib and a similar drug called: sorafinib), will probably change the standard first line therapy for patients with metastatic renal (kidney) cancer.